StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report released on Sunday. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Trading Up 0.6 %
OPGN stock opened at $1.96 on Friday. The company has a 50 day moving average of $1.84 and a two-hundred day moving average of $2.48. OpGen has a 12-month low of $1.40 and a 12-month high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last announced its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Further Reading
- Five stocks we like better than OpGen
- What is a Low P/E Ratio and What Does it Tell Investors?
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- How Technical Indicators Can Help You Find Oversold Stocks
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
